☰

Joshua F. Heiber, Ph.D. - Publications

Affiliations: 
2011 Microbiology and Immunology (Medicine) University of Miami, Coral Gables, FL 
Area:
Virology Biology, Immunology
Tree Info Similar researchers PubMed Report error

12 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Kurisetty VV, Heiber J, Myers R, Pereira GS, Goodwin JW, Federspiel MJ, Russell SJ, Peng KW, Barber G, Merchan JR. Preclinical safety and activity of recombinant VSV-IFN-β in an immunocompetent model of squamous cell carcinoma of the head and neck. Head & Neck. 36: 1619-27. PMID 24115092 DOI: 10.1002/Hed.23502  0.548
2012 Heiber JF, Barber GN. Evaluation of innate immune signaling pathways in transformed cells. Methods in Molecular Biology (Clifton, N.J.). 797: 217-38. PMID 21948479 DOI: 10.1007/978-1-61779-340-0_15  0.638
2011 Heiber JF, Xu XX, Barber GN. Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer. Chinese Journal of Cancer. 30: 805-14. PMID 22059911 DOI: 10.5732/Cjc.011.10205  0.605
2011 Heiber JF, Barber GN. Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent. Journal of Virology. 85: 10440-50. PMID 21813611 DOI: 10.1128/Jvi.05408-11  0.642
2011 Elsby R, Heiber JF, Reid P, Kimball SR, Pavitt GD, Barber GN. The alpha subunit of eukaryotic initiation factor 2B (eIF2B) is required for eIF2-mediated translational suppression of vesicular stomatitis virus. Journal of Virology. 85: 9716-25. PMID 21795329 DOI: 10.1128/Jvi.05146-11  0.653
2011 Kurisetty V, Heiber J, Perreira G, Goodwin J, Peng KW, Barber G, Merchan J. Abstract 4313: Preclinical safety and efficacy of VSV-IFN-b in a syngeneic, immunocompetent model of head and neck squamous cell carcinoma Cancer Research. 71: 4313-4313. DOI: 10.1158/1538-7445.Am2011-4313  0.596
2011 Gutman D, Heiber J, Elsby R, Barber G. PS2-074 Development of recombinant vesicular stomatitis virus for use as oncolytic vector Cytokine. 56: 84. DOI: 10.1016/J.Cyto.2011.07.237  0.699
2011 Heiber JF, Ahn J, Barber GN. PS2-068 Vesicular stomatitis virus (VSV) expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent Cytokine. 56: 83. DOI: 10.1016/J.Cyto.2011.07.231  0.625
2010 Capo-chichi CD, Yeasky TM, Heiber JF, Wang Y, Barber GN, Xu XX. Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models. Gynecologic Oncology. 116: 269-75. PMID 19932656 DOI: 10.1016/J.Ygyno.2009.10.086  0.581
2010 Heiber JF, Acevedo J, Gutman D, Elsby R, Barber GN. SS5-7 Development of recombinant vesicular stomatitis virus that modulate immunity for use as an oncolytic vector Cytokine. 52: 45. DOI: 10.1016/J.Cyto.2010.07.432  0.694
2009 Chakraborty P, Seemann J, Mishra RK, Wei JH, Weil L, Nussenzveig DR, Heiber J, Barber GN, Dasso M, Fontoura BM. Vesicular stomatitis virus inhibits mitotic progression and triggers cell death. Embo Reports. 10: 1154-60. PMID 19745842 DOI: 10.1038/Embor.2009.179  0.583
2009 Heiber J, Hyun J, Obuchi M, Barber GN. Development of recombinant vesicular stomatitis virus for use as an oncolytic vector in cancer therapy Cytokine. 48: 47. DOI: 10.1016/J.Cyto.2009.07.130  0.754
Show low-probability matches.